Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Size Share - Emerging Evolution, Advancement, Industry Trends and Forecast 2018-2026

Exocrine Pancreatic Insufficiency (EPI)
Therapeutics Market: New Business
Opportunities and Investment
Research Report 2018-2026
Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market, by
Disease Management (Nutritional Management and Pancreatic
Enzyme Replacement Therapy (PERT)), by Therapeutic Drugs (Creon,
Zenpep, Pancreaze, Ultresa, Viokace, and Others), and by Geography
(North America, Europe, Latin America, Asia Pacific, Middle East, and
Africa) - Size, Share, Outlook, and Opportunity Analysis 2018–2026
Exocrine pancreatic insufficiency (EPI) is a condition associated with deficiency of exocrine pancreatic
enzymes that results in the inability to digest food or maldigestion. EPI may be associated with certain
diseases and conditions that affect the pancreas such as cystic fibrosis, chronic pancreatitis,
Shwachman–Diamond syndrome, and others. Chronic pancreatitis (CP) is the most common cause of
EPI in adults that is followed by cystic fibrosis (CF). CF is an inherited genetic condition that leads to
chronic disease, which affects lungs, digestive, and reproductive system. Patients suffering from
exocrine pancreatic insufficiency cannot properly digest proteins, fats, and carbohydrates in the food
that results in poor absorption of nutrients in the body.
Furthermore, EPI is associated with uncomfortable gastrointestinal (GI) symptoms such as bloating,
gas, and oily diarrhea that floats and is difficult to flush. The symptoms of EPI may be similar to other
gastrointestinal disorders such as Crohn’s disease, celiac disease, irritable bowel syndrome (IBS),
ulcerative colitis, and small intestinal bacterial overgrowth (SIBO), which makes EPI difficult to
diagnose. However, there are three major tests used for diagnosis of EPI that include, fecal elastase test,
fecal fat test, and direct pancreatic function test.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market – Drivers
Exocrine pancreatic insufficiency is associated with certain diseases and conditions such as chronic
pancreatitis, cystic fibrosis, pancreatectomy, pancreatic cancer, gastrointestinal surgery, type I and type
III C diabetes, and other conditions including autoimmune pancreatitis, celiac disease, and
inflammatory bowel disease. Moreover, high prevalence of these conditions leads to EPI, which in turn
fuels growth of exocrine pancreatic insufficiency (EPI) therapeutics market. For instance, according to
a report by the Cystic Fibrosis Foundation, 2010, around 1,000 new cases of cystic fibrosis are
diagnosed globally every year.
According to a report by the Diabetes.co.uk, 2018, EPI was more evident in the people with insulindependent diabetes. According to the same source, in 2003, a study conducted on around 1,000 diabetic
patients found that insulin-dependent diabetes was more likely to produce abnormally low levels of
exocrine pancreatic enzymes. Furthermore, between 25% and 50% of insulin-dependent diabetes
patients were found to have developed exocrine pancreatic insufficiency. Moreover, high prevalence of
diabetes may increase the risk of EPI. For instance, according to International Diabetes Federation
(IDF) Diabetes Atlas: 2017, number of people with diabetes, worldwide, aged between 20 to 79 years
in 2017 was around US$ 425 million, and the number is estimated to increase to 48% in 2045,
accounting for around US$ 629 million.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market – Regional Analysis
Geographically, the global exocrine pancreatic insufficiency (EPI) therapeutics market is segmented
into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America is
expected to dominate the global exocrine pancreatic insufficiency (EPI) therapeutics market due to
increasing incidence and prevalence cases of these conditions occurring in this region. EPI is mostly
characterized with its associated conditions such as cystic fibrosis, pancreatic cancer, chronic
pancreatitis, gastrointestinal surgery, and others.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market – Competitive Analysis
Key players operating in the exocrine pancreatic insufficiency (EPI) therapeutics market include,
AbbVie, Inc., Digestive Care, Inc., Janssen Pharmaceuticals, Inc., Anthera Pharmaceuticals, Inc.,
Allergan plc, AzurRx BioPharma, Inc., and others. Key players operating in this market are focused on
product regulatory approvals and acquisition strategies to enhance their share in the market. For
instance, in May 2013, AbbVie, Inc. announced the availability of CREON (pancrelipase) 36,000
Lipase-unit Capsules for patients with EPI in the U.S. Furthermore, in May 2018, VIVUS, Inc. entered
into definitive agreement with Janssen Pharmaceuticals, Inc. to acquire all the product rights for
PANCREAZE (pancrelipase) delayed-release capsules in the U.S. and Canada.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/2020
Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market – Taxonomy
By Disease Management
• Nutritional Management
• Pancreatic Enzyme Replacement Therapy (PERT)
By Therapeutic Drugs
•
•
•
•
•
•
Creon
Zenpep
Pancreaze
Ultresa
Viokace
Others
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Exocrine pancreatic insufficiency (EPI) is a condition associated with deficiency of exocrine pancreatic enzymes that results in the inability to digest food or maldigestion. EPI may be associated with certain diseases and conditions that affect the pancreas such as cystic fibrosis, chronic pancreatitis, Shwachman–Diamond syndrome, and others. Chronic pancreatitis (CP) is the most common cause of EPI in adults that is followed by cystic fibrosis (CF). CF is an inherited genetic condition that leads to chronic disease, which affects lungs, digestive, and reproductive system. Patients suffering from exocrine pancreatic insufficiency cannot properly digest proteins, fats, and carbohydrates in the food that results in poor absorption of nutrients in the body.